Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 24, Issue 7, 2002, Pages 431-455

  Bayes M ^a   Rabasseda, X ^a   Prous, J R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALISKIREN; ALTEPLASE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ESOMEPRAZOLE; FOSINOPRIL; HEPARIN; HYDROCHLOROTHIAZIDE; LANSOPRAZOLE; LISINOPRIL; LOSARTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; OMEPRAZOLE; PANTOPRAZOLE; PENTOXIFYLLINE; PROBUCOL; RISEDRONIC ACID; ROFECOXIB; ROSIGLITAZONE; SERTRALINE; STREPTOKINASE; TEGASEROD; UNINDEXED DRUG; VALSARTAN; VARDENAFIL;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG COST; DRUG INFORMATION; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; SECONDARY HYPERPARATHYROIDISM; DRUG THERAPY; INTERNET; METHODOLOGY; PRACTICE GUIDELINE; REVIEW; STANDARD;

CLINICAL TRIALS; DRUG THERAPY; HUMANS; INTERNET; PRACTICE GUIDELINES;

EID: 0036750340     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (170)

1. Sliwa, K. et al. Effects of pentoxifylline in severe heart failure. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 421B.
2. Feliciano, N. et al. Valsartan showed improved outcome in heart failure patients regardless of whether patients after discontinuation of trial treatment were censored. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 406B.
3. Tatu-Chitoiu, G. Similar efficacy and safety of a new accelerated streptokinase regimen (1. 5MU in 20 min.) as compared to the front-loaded alteplase in patients with acute myocardial infarction. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 204B.
4. Thadani, U., Mazzu, A. Exercise-induced ischemia was not adversely effected by vardenafil during an exercise stress test in men with coronary artery disease. Eur Urol Suppl 2002, 1(1): Abst 595.
5. Serebruany, V.L. et al. Effects of zoloft on platelet/endothelial biomarkers in depressed patients after acute coronary events: Sertraline antidepressant heart attack randomized trial (SAD-HART platelet substudy). J Am Coll Cardiol 2002, 39 (9, Suppl. B): 223B.
6. Sliwa, K. et al. C-reactive protein predicts improved sytolic performance in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 192B.
7. Stanton, A., Barton, J., Jensen, C., Bobillier, B., Mann, J., O'Brien, E. Dose response antihypertensive efficacy of aliskiren (SPP 100), an orally active renin inhibitor. Am J Hypertens 2002, 15 (4, Part 2): Abst P-67.
8. Ruilope, L.M., Luque-Otero, M., Plouin, P. et al. The selective aldosterone blocker eplerenone is superior to losartan in patients with low-renin hypertension. J Hypertens 2002, 20 (Suppl. 4): Abst P0709.
9. White, W.B., Oigman, W., Mion, D. et al. Assessment of the new selective aldosterone blocker eplerenone on 24-hour ambulatory blood pressure. J Hypertens 2002, 20 (Suppl. 4): Abst P0710.
10. White, W.B., Duprez, D., Van Mieghem, W., Roniker, B., Kleiman, J., Krause, S. The selective aldosterone blocker eplerenone versus amlodipine for the treatment of systolic hypertension in older people. J Hypertens 2002, 20 (Suppl. 4): Abst P0711.
11. Kan, K.P. et al. Effects of fixed-dose combination fosinopril/hydrochlorothiazide on blood pressure in uncontrolled hypertension. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 168B.
12. Arnopolskaya, D.I. Effects of 6-monthly therapy of valsartan and lisinopril on left ventricular mass and diastolic function in patients with mild-to-moderate arterial hypertension. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 237B.
13. Chan, L. et al. The impact of antihypertensive treatment on atherogenesis process in essential hypertension: Valsartan versus diuretic. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 169B.
14. Prost, H., Padma-Hathan, H., Thibonnier, M., Eardley, I. Efficacy and sajery of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Eur Urol Suppl 2002, 1(1): Abst 599.
15. Padma-Nathan, H. et al. Efficacy and safety of vardenafil, a selective phosphodiesrerase 5 inhibitor; in men with erectile dysfunction on antihypertensive therapy. Am J Hypertens 2002, 15 (4, Part 2): Abst P-42.
16. White, W. et al. Rofecoxib, but not celecoxib, increases systolic blood pressure in hypertensive patients treated with ACE inhibitors and beta-blockers. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0247.
17. Shyu, K.-G., Chang, H., Wang, B.-W., Kuan, P. Intramuscular gene therapy for critical limb ischemia with occlusive peripheral arterial disease in Chinese patients. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 81B.
18. Yong, G. et al. Effects of alendronate on biochemical variables and bone mineral densitometry post-cardiac transplantation. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 392B.
19. Lauritsen, K. et al. Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed reflux oesophagitis. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst L.B.034.
20. Walqvist, P. et al. Esomeprazole is cost-effective compared with lansoprazole in the acute and maintenance treatment of reflux oesophagitis in the UK. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst L.B.051.
21. Lind, T. et al. Esomeprazole and lansoprazole in the management of patients with reflux oesophagitis (RO): Combining results from two clinical studies. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst L.B.052.
22. Roach, A. et al. Evidence-based analysis of the benefit of esomeprazole in the treatment of erosive esophagitis (EE). J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.069.
23. Castell, D.O. et al. Esomeprazole is more effective than lansoprazole for treating daily and nocturnal heartburn (HB) in GERD patients with erosive esophagitis (EE). J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.094.
24. Malfertheiner, P. et al. The impact of Helicobacter pylori status on healing of erosive and non-erosive GERD with esomeprazole: An analysis based on the ProGERD study initiative. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.092.
25. Talley, N. et al. On-demand treatment with esomeprazole: Relationship between dosing frequency and antacid use in patients with endoscopy-negative gastroesophageal reflux disease. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.099.
26. Wilder-Smith, C. et al. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.067.
27. Thomson, A.B.R. et al. Esomeprazole 40 mg provides more effecrive acid control than lansoprazole 30 mg following single dose administration. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.089.
28. Johnsson, F. et al. One-week esomeprazole treatment; an effective confirmatory test in patients with suspected gastroesophageal reflux disease. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.029.
29. Röhss, K. et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.090.
30. Eissele, R. et al. Efficacy and safety of pantoprazole 20 mg o.d. (PANTO) for the acute and prophylactic treatment of mild GERD. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.033.
31. Simon, B. et al. Equivalent effect of pantoprazole 40 mg o.d. and esomeprazole 40 mg o.d. on intra esophageal pH in patients with symptomatic GERD. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.087.
32. Schoenfeld, P., Drossman, D., Chey, W.D., Kim, H.M., Thompson, W.G. Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: A meta-analysis of randomized controlled trials. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst T1486.
33. Tack, J., Delia, T., Ligozio, G., Sue, S., Lefkowitz, M., Vandeplassche, L. A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) patients with normai gastric emptying (NGE). Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst 154.
34. Thomson, A. et al. Risedronate is associated with a lower incidence of gastric ulcers than alendronate: Results from two comparative studies. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.Q.003.
35. Serclova, Z., Antos, F. Local application of glutamin in the therapy of pouchitis. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.E.083.
36. Manning, D.C. et al. Temporal aspects of COX189 efficacy in acute dental pain. Clin Pharmacol Ther 2002, 71(2): Abst MPI-47.
37. Gordon, F.H., Hamilton, M.I., Donoghue, S. et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16(4): 699.
38. Guevarra, M., Abecasis, R., Jimenez, W., Rios, H., Terg, R. Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study. J Hepatol 2002, 36 (Suppl. 1): Abst 719.
39. Pemberton, P., Aboutwerat, A., Smith, A. et al. Long term ursodeoxycholic acid (URSO) treatment improves glutathione status in primary biliary cirrhosis (PBC). J Hepatol 2002, 36 (Suppl. I): Abst 562.
40. Merat, S. et al. Probucol in non-alcoholic steatohepatitis: Preliminary report. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.O.021.
41. Wehmeier, K.R., Neuschwander, B.A., Brunt, E.M. et al. Rosiglitazone lowers aminotransferase in nonalcoholic steatohepatitis. 84th Annu Meet Endocr Soc (June 19, 2002, San Francisco) 2002: Abst OR11-5.
42. Bozkaya, H., Yudaydin, C., Bozdayi, M., Sagiroglu, A.K., Erkan, O., Uzunalimoglu, O. Lamivudine is not effective in the treatment of non-cirrhotic HBeAg(-) chronic hepatitis B patients with low level viremia. J Hepatol 2002, 36 (Suppl. 1): Abst 351.
43. Familias, I. et al. Efficacy and safety of gancyclovir in lamivudine treated hepatitis B relapsers. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.J.011.
44. Aladag, M. et al. Interferon and lamivudine combination anti-HBe positive chronic viral hepatitis B treatment. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst L.B.014.
45. Kim, B. et al. The efficacy of lamivudine and alpha-interferon combination treatment in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.J.015.
46. Ding, R., Ooi, E. Durability of HBeAg responses to lamivudine in Asian Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.J.022.
47. Boyacioglu, S. et al. Lamivudine in renal transplant candidates with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.J.013.
48. Khairy, H., Meshrif, A., Bedeir, A., Shoukry, I. Early use of Viagra and antioxidants improve the return of erectile activity after radical cystoprostatectomy. Eur Urol Suppl 2002, 1 (1): Abst 597.
49. Bisgaard, T., Klarskov, B., Kehlet, H., Rosenberg, J. Preoperative dexamethasone (8 mg) in laparoscopic cholecystectomy. A randomized double-blind placebo-controlled trial. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.U.008.
50. Benhamou, Y., Bochet, M., Tubiana, R. et al. Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV. J Hepatol 2002, 36 (Suppl. 1): Abst 495.
51. Bellibas, S.E., Pepper, T., Dorr, A. et al. Pharmacokinetics and safety of 2 mg/kg T-20 in combination therapy in HIV infected children and adolescents. 14th Int AIDS Conf (July 7, 2002, Barcelona) 2002: Abst TuPeB4632.
52. Clotet, B., Lazzarin, A., Cooper, D. et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved anriretrovirals (ARVs) in Europe and Australia. 14th Int AIDS Conf (July 7, 2002, Barcelona) 2002: Abst LbOr19A.
53. Henry, K., Lalozeri, J., O'Hearn, M. et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil. 14th Int AIDS Conf (July 7, 2002, Barcelona) 2002: Abst LbOr19B.
54. Piliero, P., Cahn, P., Pantaleo, G. et al. Atazanavir: A once-daily protease inhibitor with a superior lipid profile: Results of clinical trials beyond week 48. 9th Conf Retroviruses Opportunistic Infect (Feb 24, 2002, Seattle) 2002: Abst 706-T.
55. Mynarcik, D.C., Combs, T.P., McNurlan, M.A., Scherer, P.E., Gelato, M.C. Rosiglitazone-mediated improvement of insulin sensitivity is highly correlated with increases in circulating Acrp30/adiponectin in HIV-associated lipodystrophy. 84th Annu Meet Endocr Soc (June 19, 2002, San Francisco) 2002: Abst OR11-4.
56. Pfuetzner, A. et al. Variability of insulin absorption after subcutaneous and pulmonary application in patients inpatients with Type 2 diabetes. Diabetes 2002, 51 (Suppl. 2): Abst 193-OR.
57. Kim, D., Mudaliar, S., Plodkowski, R. et al. Dose-response relationships of inhaled and subcutaneous insulin in type 2 diabetic patients. Diabetes 2002, 51 (Suppl. 2): Abst 192-OR.
58. Hermansen, K. et al. Intensive treatment with pulmonary insulin using the A ERx(R) insulin Diabetes Management System - A proof of concept trial in type 2 diabetic patients. Diabetes 2002, 51 (Suppl. 2): Abst 194-OR.
59. Litchy, W., Dyck, P., Tesfaye, S., Zhang, D., Bastyr, E. Diabetic peripheral neuropathy (DPN) assessed by neurological examination (NE) and composite scores (CS) is improved with LY333531 treatment. Diabetes 2002, 51 (Suppl. 2): Abst 800-P.
60. Vinik, A., Tesfaye, S., Zhang, D., Bastyr, E. LY333531 treatment improves diabetic peripheral neuropathy (DPN) with symptoms. Diabetes 2002, 51 (Suppl. 2): Abst 321-OR.
61. Mohanty, P., Aljada, A., Ghanim, H. et al. Evidence for a potent anti-inflammatory effect of rosiglitazone in obese diabetic patients. 84th Annu Meet Endocr Soc (June 19, 2002, San Francisco) 2002: Abst P2-376.
62. Ghanim, H., Aljada, A., Mohanty, P., Hofmeyer, D., Oo, T., Dandona, P. Rosiglotazone suppresses early growth response-1 (Egr-1) gene and plasminogen activator inhibitor-1 (PAI-1). 84th Annu Meet Endocr Soc (June 19, 2002, San Francisco) 2002: Abst OR 11-3.
63. Ghanim, H., Aljada, A., Mohanty, P. et al. Troglitazone suppresses pro-inflammatory transcription factors, early growth response-1 (Egr-1) and activator protein-1 (AP-1) in mononuclear cells (MMC): Further evidence of the anti-inflammatory effects of troglitazone. 84th Annu Meet Endocr Soc (June 19, 2002, San Francisco) 2002: Abst P2-372.
64. Sommer, F., Schwarzer, U., Christoph, A. et al. The effect of long-term testosterone replacement therapy on prostate specific antigen and prostate volume in hypogonadal men - Results of a prospective study. Eur Urol Suppl 2002, 1 (1): Abst 235.
65. Suárez-Otero, R. et al. Efficacy and safety of diclofenaccholestyramine and celecoxib in osteoarthritis: A randomized, double-blind study. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0200.
66. Stengaard-Pedersen, K. et al. Comparison of 3 different dosing regimens of celecoxib for the treatment of osteoarthritis of the knee or hip. A Nordic, 12-week, randomized, double-blind study. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst AB0292.
67. Hawkey, C. et al. Reduced cumulative incidence of gastroduodenal ulcers with two doses of a new coxib, COX189 compared with standard therapeutic doses of ibuprofen in osteoarthritis patients. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst M1732.
68. Hawkey, C.J. et al. Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, COX189 compared with ibuprofen in osteoarthritis patients. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0226.
69. Karastatev, D.S. Osteoarthritis treated with COX-2 selective drugs and gastroduodenal injury. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst AB0294.
70. Singh, G., Fort, J. Efficacy of celecoxib and rofecoxib: Is there any clinically important difference? Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst FRI0120.
71. Wong, J.M., Pena, B.M., Recker, D.P. Valdecoxib improves dyspepsia-related health in patients with osteoarthritis. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0257.
72. Schoen, E. et al. Patient satisfaction with celecoxib compared to traditional NSAID therapy in "usual" rheumatology clinical practice: The success-IV clinical trial. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0256.
73. Moore, A. et al. Responder rate of COX189 in osteoarthritis: A multi-national study. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0265.
74. Pincus, T. et al. Celecoxib 200 mg QD and rofecoxib 25 mg QD show similar efficacy in the treatment of a flare of osteoarthritis. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0245.
75. Goldstein, J. et al. Differential rates of UGI symptoms in patients receiving celecoxib vs rofecoxib with and without low-dose aspirin for cardiovascular prophylaxis. Eur Leag Against Rheum Congr (June 12. 2002, Stockholm) 2002: Abst THU0246.
76. Makarowski, W.S., Zhao, W.W., Bevirt, T., Recker. D.P. The COX-2 specific inhibitor valdecoxib is effective in treating symptomatic osteoarthritis of the hip. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0203.
77. Kivitz, A.J., Eisen, G., Zhao, W.W., Bevirt, T., Recker, D.P., Verburg, K.M. The COX-2 specific inhibitor valdecoxib is as effective as the conventional NSAID naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration. Eur Leag Against Rheum Congr (June 12. 2002, Stockholm) 2002: Abst THU0205.
78. Makuch, R. et al. Switching of prescription anti-inflammatorv therapy among enrollees in a U.S. managed care organization: A comparison of non-selective NSAIDs, celecoxib, and rofecoxib. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst AB0533.
79. Makuch, R. et al. Medical costs of cardiovascular, renal, and upper gastrointestinal impatient and outpatient claims: A comparison between celecoxib and rofecoxib. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst SAT0346.
80. Makuch, R. et al. Comparative costs of COX-2 specific inhibitors in a US managed care organization: Medication, gastrointestinal, cardiovascular, and renal-specific costs. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst SAT0345.
81. Singh, G. et al. Effect of concurrent low-dose aspirin (ASA) use on the incidence of UGI symptoms in patients receiving celecoxib or conventional NSAIDs: Analysis of two large randomized, double-blind, controlled clinical studies. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0267.
82. Rau, R., Herborn, G., Wasenberg, S. et al. 2. 5-Year treatment results with adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, in combination with methotrexate in active rheumatoid arthritis. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst OP0073.
83. Bensen, W.G., Weaver, A., Espinoza, L. et al. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0073.
84. McKenna, F., Recker, D.P., Verberg, K.M. Valdecoxib, a potent COX-2 specific inhibitor is as effective as diclofenac in the management of rheumatoid arthritis and has a lower incidence of gastroduodenal ulcers. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst FRI0040.
85. Weisman, M. et al. A double-blind, placebo-controlled trial of VX-745, an oral p38 mitogen activated protein kinase (MAPK) inhibitor; in patients with rheumatoid arthritis (RA). Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst FRI0018.
86. Allaart, R. et al, Two pilot studies of VX-745, an oral p38 mitogen activated protein kinase (MAPK) inhibitor in patients with rheumatoid arthritis (RA). Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst FRI0046.
87. Zaknoen, S.L. et al. Phase I study of oral lonafarnib plus docetaxel as second-line treatment for advanced solid tumors. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 2136.
88. Tasmuth, T., Härtel, B., Kalso. E. Venlafaxine in neuropathic pain following treatment of breast cancer: Eur J Pain 2002, 6(1): 17.
89. Basu, S., Biyani, C.S., Prescott, S., Puri, R. Intravesical bacillus Calmette-Guerin (BCG) - A survey of the practise patterns of urologists across the British Isles. Eur Urol Suppl 2002, 1(1): Abst 392.
90. Nogueira March, J.L., Solsona, E., Unda, E. et al. A multicentre and randomised prospective study comparing three intravesical therapies, two with bacillus Calmette-Guerin (BCG) immunotherapy and one with mitomycin-C chemotherapy in medium and low risk supeficial bladder tumours. Eur Urol Suppl 2002, 1(1): Abst 393.
91. Taipale, L., Permi, J., Viitanen, J. et al. The effect of BCG and mitomycin C instillation treatment in recurrent superficial bladder carcinoma. 15-Year follow-up of a randomised prospective Finn bladder study. Eur Urol Suppl 2002, 1(1): Abst 395.
92. Kaasinen, E., Wijkström, H., Malmström, P.-U. et al. Alternating mitomycin C and BCG instillations versus BCG alone in the treatment of carcinoma in situ of the urinary bladder. A Nordic study. Eur Urol Suppl 2002, 1(1): Abst 396.
93. Storti, L., Giurioli, A., Zampa, G. et al. Intravesical bacillus Calmette-Guerin vs passive diffusion and electromotive administration of mitomycin C in patients with carcinoma in situ of the bladder: A randomised cross over study. Eur Urol Suppl 2002, 1(1): Abst 478.
94. Cunningham, D. et al. Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra™) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 2002, 21: (Part 1): Abst 502.
95. Bleumer, I., Beck, J., Hofmann, R. et al. A phase II trial with monoclonal antibody WX-G250 in advanced renal cell carcinoma. Eur Urol Suppl 2002, 1(1): Abst 437.
96. Irani, J., Ravery, V., Patient, J.-L. et al. Nonsteroidal anti-inflammatory agents and finasteride and risk for prostate cancer. Eur Urol Suppl 2002, 1(1): Abst 296.
97. Gravis, G. et al. Chemotherapy with a weekly administration of docetaxel for metastatic hormone refractory prostate cancer (HRPC). Evaluation of tolerance, quality of life (QoL), and clinical benefit. Eur Urol Suppl 2002, 1(1): Abst 624.
98. Canelas, A. Docetaxel in combination with estramustine phosphate in patients with hormone refractory prostate cancer (HRPC): A phase II study. Eur Urol Suppl 2002, 1(1): Abst 623.
99. Kuhn, J.G. et al. Phase I trial of R115777 (Zarnestra) in patients with recurrent malignant glioma taking enzyme inducting antiepileptic drugs (EIAED). A North American brain tumor consortium (NABTC) report. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 342.
100. Harousseau, J.-L. et al. Interim results from a phase II study of R115777 (Zarnestra) in patients with relapsed and refractory acute myelogenous leukemia. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 1056.
101. Gotlib, J. et al. Phase I/II study of farnesyltransferase inhibitor R115777 (Zanestra) in patients with myeloproliferative disorders (MPDs): Preliminary results. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 14.
102. Metz, L. M. et al. Depression in MS: The relationship to interferon therapy. 54th Annu Meet Am Acad Neurol (April 13. 2002, Denver) 2002: Abst P03.025.
103. Miller, J.R., Fowler, C.J. Efficacy of sildenafil citrate in men with erectile dysfunction and multiple sclerosis: Results of an openlabel study. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P06.087.
104. Rozen, T.D. Treatment of hemicrania continua with high dose celecoxib and rofecoxib. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P06.115.
105. Diener, H.C., Jansen, J.-P., Reches, A., Pascual, J., Pitei, D., Steiner, T.J. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002, 47(2): 99.
106. Kenney, C. et al. A double-blind, placebo-controlled, modified crossover pilot study of the effects of Ginkgo biloba on cognitive and functional abilities in multiple sclerosis. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P06.081.
107. Lublin, F. et al. Results of the extension of a trial to assess the longer term sqfety of combining interferon beta-1a and glatiramer acetate. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst S 13.003.
108. Radue, E.-W. et al. MRI results of the European interferon beta-1a dose-comparison study. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P03.069.
109. Miller, D.M. et al. Assessing the effects of IFNbeta-1a on health related quality of life in secondary-progressive MS patients: Results from the IMPACT study. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P06.075.
110. Navan, P. et al. A double-blind single dose cross-over study of the effects of pramipexole, pergolide and placebo on tremor and UPDRS (III) in Parkinson's disease. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P06.110.
111. Stiasny, K. et al. Cabergoline in RLS - A double-blind placebo-controlled multicenter dose-finding trial. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P06.020.
112. Sechi, G., Agnetti, V., Sulas, M.I.F., Pitzolu, M.G., Rosati, G. Effects of topiramate in patients with cerebellar tremor. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.I.E.078.
113. Lôo, H., D'Haenen, H., Hale, A. S-20098 in patients with major depressive or bipolar II disorders: Effect on individual depressive symptoms. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.3.E.034.
114. Lôoo, H., D'Haenen, H., Hale, A. A double-blind trial of S-20098 in patients with major depressive or bipolar II disorders: Dose-ranging study. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.3.E.033.
115. Lôo, H., D'Haenen, H., Hale, A. A double-blind study of S-20098 in patients with major depressive or bipolar II disorders: Effect on remission. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.3.E.030.
116. Lôo, H., D'Haenen, H., Hale, A. S-20098 in patients with major depressive or bipolar II disorders: Efficacy in severely depressed patients. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.3.E.032.
117. Lôo, H., D'Haenen, H., Hale, A. A double-blind study of S-20098 in patients with major depressive or bipolar II disorders: Effect on anxiety. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.3.E.031.
118. McIntyre, R., Mancini, D.A., McCann, S.M., Srinavasan, J., Sagman, D., Kennedy, S. H. Randomised, single-blind comparison of topiramate and bupropion SR in bipolar depression. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.1.E 005.
119. Vieta, E., Parramon, G., Goikolea, J.M. et al. Adjunctive topiramate in bipolar II disorder. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.1.E.006.
120. Vieta, E., Ros, S., Valle, J., Crespo, J.M., Valls, J., Salgado, P. A multicentre study of the efficacy and safety of topiramate in mania. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.1.E.007.
121. Vieta, E., Goikolea, J.M., Benabarre, A., Comes, M., Reinares, M., Martinez-Aran, A. Risperidone and topiramate co-therapy in bipolar disorder. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.2.E.045.
122. Feighner, J.P., Sverdlov, L., Abajian, H., Nicolau, G., Hlavka, J., Freed, J. Pilot study with nemifitide in patients with severe treatment-resistant depression. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.4.W.016.
123. Robinson, D.S. et al. Efficacy and safety results of two phase III studies with the selegiline transdermal system in the treatment of major depression. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): Abst P.3.E.016.
124. Sussman, D. Dry mouth is more pronounced in patients with overactive bladder treated with extended release oxybutynin compared to tolterodine. Eur Urol Suppl 2002, 1(1): Abst 523.
125. Abrams, P., Kaplan, S., Millard, R. Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity. Eur Urol Suppl 2002, 1 (1): Abst 520.
126. Batinic, D., Muertz, G., Schnabel, F., Gramatté T., Kirch, W. Efficacy and tolerability of propiverine in children suffering from overactive bladder - A double-blind, randomised, clinical trial versus oxybutynin and placebo. Eur Urol Suppl 2002, 1 (1): Abst 442.
127. Mattiason, A., Massey, D. Tolterodine treatment augmented by simplified bladder training in overactive bladder (OAB) patients. Eur Urol Suppl 2002, 1(1): Abst 524.
128. Palma, P., Cassio, R., Hermann, V., Dambros, M., Thiel, M., Netto, N. Jr. Resiniferatoxin: A progress in the treatment of refractory urinary dysfunction. Eur Urol Suppl 2002, 1(1): Abst 153.
129. Kim, E.H. et al. Rapid steroid withdrawal versus standard treatment in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in kidney transplantation: A 2-year follow up. Am J Transplant 2002, 2 (Suppl. 3): Abst 1029.
130. Kloner, R.A., Watkins, V.S., Costigan, T.M., Bedding, A., Mitchell, M.I., Emunick, J. Cardiovascular profile of tadalafil, a new PDE5 inhibitor J Urol 2002, 167 (4, Suppl.): Abst 707.
131. Padma-Nathan, H., Brock, G., McMahon, C. et al. Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension. Am J Hypertens 2002, 15 (4, Part 2): Abst P-313.
132. Brock, G., McMahon, C., Chen, K.-K. et al. Efficacy and safety of tadalafil in men with erectile dysfunction: An integrated analysis of registration trials. J Urol 2002, 167 (4, Suppl.): Abst 713.
133. McMahon, C.G., Brock, G.B., Chen, K.-K. et al. Tadalafil significantly improves erectile function in men with ED: Integrated analysis of registration trials. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 43B.
134. Mitchell, M. et al. Cardiovascular profile of tadalafil, a new PDE5 inhibitor: J Hypertens 2002, 20 (Suppl. 4): Abst P1053.
135. Porst, H., Rosen, R.C., Padma-Nathan, H., Varanese, L., Anglin, G., Giuliano, F. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. J Urol 2002, 167 (4, Suppl.): Abst 709.
136. Brock, G., Terry, T., Monica, S. et al. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Eur Urol Suppl 2002, 1(1): Abst 598.
137. Goldfischer, E., Eardley, I., Segerson, T. Vardenafil improves erectile function in men with significant comorbidities associated with erectile dysfunction (ED). J Urol 2002. 167 (4, Suppl.): Abst 714.
138. Padma-Nathan, H., Eardley, I., Collins, O., Segerson, T. Vardenafil restores normal functioning to men with erectile dysfunction. J Urol 2002, 167 (4, Suppl.): Abst 710.
139. Donatucci, C., Eardley, I., McVary, K.T., Thibonnier, M. Vardenafil improves erectile function regardless of etiology or baseline severity in men with erectile dysfunction. J Urol 2002, 167 (4, Suppl.): Abst 715.
140. Donatucci, C., Karlin, G., Goldfischer, E., Cohen, S., Thibonnier, M. Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dvsfunction. J Am Geriatr Soc 2002, 50 (4, Suppl.): Abst P293.
141. Barkin, J., Guimaraes, M., Do Castelo, V, et al. Dutasteride provides sustained symptom relief following short term combination treatment with tamsulosin. J Urol 2002, 167 (4, Suppl.): Abst 1481.
142. Roehrborn, C., Andriole, G., Boyle, P., Höfner, K. Effect of the dual 5alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume. Eur Urol Suppl 2002, 1(1): Abst 417.
143. Andriole, G., Roehrborn, C.G., Boyle, P. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum total PSA, free PSA and the ratio of F/T PSA. J Urol 2002, 167 (4, Suppl.): Abst 844.
144. Roehrborn, C.G., Ramsdell, J., Siami, P., Wachs, B.H., Rosenblatt, S. Prostate volume at baseline predicts the margin of therapeutic response with the 5alpha-reductase inhibitor; dutasteride. J Urol 2002, 167 (4, Suppl.): Abst 1483.
145. Boyle, P.P., Siami, P., Wachs, B.H., Roehrborn, C.G., Andriole, G., Nickel, C. Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment. J Urol 2002, 167 (4, Suppl.): Abst 1479.
146. Roehrborn, C.G., Andriole, G., Nickel, C., Boyle, P. Effect of the dual 5α-reductase inhibitor dutasteride on endocrine parameters. J Urol 2002, 167 (4, Suppl.): Abst 1049.
147. Roehrborn, C.G., Andriole, G., Nickel, C., Boyle, P., Ramsdell, J., Rosenblatt, S. Effect of dutasteride, a novel dual 5alpha-reductase inhibitor, on BPH related signs and symptoms. J Urol 2002, 167 (4, Suppl.): Abst 1043.
148. Strohmeyer, D., Wolfgang, H., Georg, B., Eberhard, G., Hermann, R. Is there an influence of finasteride on angiogenic status in patients with benign prostate hyperplasia (BPH)? Eur Urol Suppl 2002, 1(1): Abst 237.
149. Roehrborn, C. Rapid reduction in risk of AUR and/or surgery with finasteride in men with benign prostatic hyperplasia. Eur Urol Suppl 2002, 1(1): Abst 419.
150. Debruyne, F. Comparison of a phytotherapeutic agent (Permixon) with an alpha blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: A I-year randomised international study. Eur Urol Suppl 2002, 1(1): Abst 424.
151. Glémain, P., Grapin, F., Coulange, C., Muszynski, R. What is the benefit of combining tamsulosin with Serenoa repens versus tamsulosin alone on storage/filling and voiding lower urinary tract symptoms (LUTS)? Eur Urol Suppl 2002, 1(1): Abst 423.
152. Hunter, W. Long-term treatment with finasteride: Sexual adverse events and fracture rates. Eur Urol Suppl 2002, 1(1): Abst 420.
153. Mirone, V., Imbimbo, C., Palmieri, A. et al. DHEA replacement therapy in female sexual dysfunction: Preliminary experience. Eur Urol Suppl 2002, 1(1): Abst 593.
154. Holgate, S., Chung, K.F., Bousquet, J., Fox, H., Surrey, K. Greatest benefit from omalizumab treatment in patients with more severe asthma. 21st Congr Eur Acad Allergol Clin Immunol (June 1, 2002, Naples) 2002: Abst 24.
155. Bousquet, J., Holgate, S., Wenzel, S., Fox, H., Gupta, N. Omalizumab is well tolerated in patients at high risk of serious asthma-related morbidity and mortality. 21st Congr Eur Acad Allergol Clin Immunol (June 1, 2002, Naples) 2002: Abst 1054.
156. Maldonado, M.R., Balasubramanyam, A., Visnergarwala, F. Use of PPAR-γ modulator rosiglitazone in normoglycemic patients with HIV lipodystrophy syndrome. 84th Annu Meet Endocr Soc (June 19, 2002, San Francisco) 2002: Abst P2-355.
157. Sharaf, H.A. et al. The effect of BQ788 on hemodynamics and aldosterone levels in healthy volunteers. J Hypertens 2002, 20 (Suppl. 4): Abst P0131.
158. VanderMaelen, C.P. et al. Dipyridamole absorption from a composite capsule vs. immediate-release tablets co-administered with aspirin in subjects with reduced stomach acidity: 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P04. 138.
159. Wilder-Smith, C.H. et al. Esomeprazole 20 mg provides more effective acid control than lansoprazole 15 mg. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.066.
160. Farouque, H.M.O. et al. The effect of gliclazide on forearm blood flow responses in health), humans. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 231B.
161. Baxter, G. et al. Lansoprazole 15 mg provides as effective acid control as esomeprazole 20 mg. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.C.080.
162. Rordorf, C., Scott, G., Blood, P. et al. Lack of gastro-duodenal erosions in healthy subjects under treatment with COX189, a COX-2 selective inhibitor Dig Dis Week (May 19, 2002. San Francisco) 2002: Abst M902.
163. Rordorf, C. et al. Treatment of healthy subjects with COX189, a COX-2 selective inhibitor: endoscopic evidence for lack of gastroduodenal erosions compared to non-selected NSAID. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0232.
164. Atherton, C.T. et al. COX-189, a new highly selective COX-2 inhibitor that lacks the ability of naproxen to enhance small bowel permeability. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst FRI0312.
165. Lamarre-Cliche, M., Bissery, A., Labatide-Alanore, A., Menard, J., Azizi, M. Pharmacodynamic effects of single oral doses of omapatrilat (40 and 80 mg) and fosinopril (20 mg) during salt depletion and salt repletion in normotensive subjects. J Hypertens 2002, 20 (Suppl. 4): Abst P0153.
166. Schwartz, J.I. et al. Comparative effects of celecoxib and rofecoxib on COX-I and COX-2 activity in whole blood assays. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0234.
167. Eriksson, K. et al. Speed of onset of intragastric acid control. Lansoprazole and esomeprazole compared. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.C.082.
168. Chang, S., Mitchell, M.I., Bedding, A.W., Emmick, J.T., Kloner, R.A. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 12B.
169. Tack, J., Vos, R., Janssens, J., Salter, J., Jauffret, S. Influence of tegaserod on proximal gastric sensory and motor function in man. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst T1308.
170. Coffin, B., Farmachidi, J.P., Bastie, A., Bouhassira, D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst M1492.